Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-07 2024-01-05 2023-07-07 2022-07-07

   
Records found: 1285
  Page 48 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-05-06 4 S $119.14 $4,053,042 D/D (34,019) 42,645     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-05-06 4 OE $21.51 $1,141,215 D/D 33,631 76,664     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-05-01 4 AS $114.98 $402,992 D/D (3,505) 248,654     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-05-01 4 AS $114.98 $2,669,517 I/I (23,218) 33,258     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-05-01 4 OE $6.46 $149,988 I/I 23,218 56,476     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-05-01 4 S $114.59 $47,442 D/D (414) 89,646     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2015-04-30 4 A $51.26 $4,511 D/D 88 79,366     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-04-30 4 A $51.26 $31,117 D/D 607 13,407     -
   Davis George Eric SVP, General Counsel   •       –      –    2015-04-30 4 A $51.26 $37,422 D/D 730 74,576     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-04-30 4 GA $0.00 $0 I/I 389 24,324     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-04-30 4 GD $0.00 $0 D/D 389 109,700     -
   Baffi Robert EVP, Technical Operations   •       –      –    2015-04-30 4 A $51.26 $19,942 D/D 389 110,089     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2015-04-30 4 A $51.26 $48,341 D/D 943 43,033     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-30 4 A $51.26 $46,547 D/D 908 252,159     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-04-30 4 A $51.26 $73,050 D/D 1,425 90,060     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-17 5 GD $0.00 $0 D/D 500 228,254     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 AS $120.53 $422,590 D/D (3,506) 251,251     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 AS $120.53 $2,717,546 I/I (22,546) 33,258     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-04-01 4 OE $6.46 $145,647 I/I 22,546 55,804     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-20 4 AS $126.40 $126,396 I/I (1,000) 33,258     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-17 4 AS $124.87 $124,866 I/I (1,000) 34,258     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2015-03-16 4 AS $123.48 $123,477 I/I (1,000) 35,258     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-03-16 4 AS $123.57 $5,105,166 D/D (41,315) 88,635     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2015-03-16 4 OE $21.51 $860,400 D/D 40,000 129,950     -
   Mueller Brian VP, Corporate Controller   •       –      –    2015-03-16 4 A $0.00 $0 D/D 4,000 12,800     -
  1285 Records found
  Previous  40  41  42  43  44  45  46  47  48  49  Next   
  Page 48 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us